199 related articles for article (PubMed ID: 17140164)
21. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
22. Comparative rates of adverse events with different formulations of intravenous iron.
Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
[TBL] [Abstract][Full Text] [Related]
23. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients.
Hoen B; Paul-Dauphin A; Kessler M
Clin Nephrol; 2002 Jun; 57(6):457-61. PubMed ID: 12078950
[TBL] [Abstract][Full Text] [Related]
24. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R; Kusek JW; Pappas MK
Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
[TBL] [Abstract][Full Text] [Related]
26. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
27. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?
Rostoker G
Semin Dial; 2019 Jan; 32(1):22-29. PubMed ID: 29956370
[TBL] [Abstract][Full Text] [Related]
28. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
29. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
30. Should intravenous iron be upfront therapy for iron deficiency anemia?
Auerbach M
Pediatr Blood Cancer; 2011 Apr; 56(4):511-2. PubMed ID: 21298731
[No Abstract] [Full Text] [Related]
31. Intravenous iron products.
Johnson CA; Mason NA; Bailie GR
ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
[TBL] [Abstract][Full Text] [Related]
32. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
35. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
37. Iron Sucrose and Blood Pressure Patterns During Hemodialysis.
Yan J; Winkelmayer WC; Walther CP
Am J Kidney Dis; 2023 Jun; 81(6):629-631. PubMed ID: 37012095
[No Abstract] [Full Text] [Related]
38. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
N Engl J Med; 2019 Jan; 380(5):447-458. PubMed ID: 30365356
[TBL] [Abstract][Full Text] [Related]
39. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
[TBL] [Abstract][Full Text] [Related]
40. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
